WATERTOWN, Mass.--(BUSINESS WIRE)--Mariana Oncology Inc., a biotechnology company pioneering a new era of radiopharmaceutical innovation to treat cancers with high unmet need, today announced the closing of an oversubscribed $175 million Series B financing co-led by Deep Track Capital and Forbion. Founding investors Atlas Venture, Access Biotechnology and RA Capital Management are joined by additional new investors Nextech Invest, Surveyor Capital (a Citadel company) and Eli Lilly and Company.

马萨诸塞州沃特敦-（商业线）-Mariana Oncology Inc.，一家开创放射性药物创新新时代的生物技术公司，用于治疗需求未得到满足的癌症，今天宣布关闭一项由B领导的1.75亿美元过度资助的B系列融资深轨资本和Forbion。创始投资者Atlas Venture，Access Biotechnology和RA Capital Management由其他新投资者Nextech Invest，Surveyor Capital（一家Citadel公司）和Eli Lilly and company加入。

Proceeds from the financing will support the advancement of Mariana Oncology’s novel portfolio of precision, next-generation radiopharmaceuticals including its lead candidate, MC-339, as the company transitions into a clinical-stage organization..

随着公司转变为临床阶段组织，融资的收益将支持Mariana Oncology新颖的下一代精确放射性药物组合的推进，包括其主要候选人MC-339。。

'The support of such a strong syndicate of new and existing investors is a testament to Mariana Oncology’s potential,” said Simon Read, Ph.D., Founder and Chief Executive Officer of Mariana Oncology. “In just 18 months since our Series A, we’ve leveraged our deep expertise in peptide discovery and radiochemistry to advance a diversified portfolio of novel molecules.

Mariana Oncology的创始人兼首席执行官Simon Read博士说：“如此强大的新旧投资者集团的支持证明了Mariana Oncology的潜力。“在我们的A系列仅仅18个月的时间里，我们利用了我们在肽发现和放射化学方面的丰富专业知识，推动了新型分子的多样化组合。

The proceeds from this financing support the advancement of our pipeline and the initial development of our lead candidate, MC-339, which we anticipate will enter the clinic in 2024 in small cell lung cancer, supported by our own GMP radiopharmaceutical manufacturing.”.

这项融资的收益支持了我们的管道的发展和我们的主要候选人MC-339的初步开发，我们预计这将在2024年进入小细胞肺癌诊所，并得到我们自己的GMP放射性药物制造公司的支持。

“Radiopharmaceuticals are now being recognized as a logistically viable treatment modality that have demonstrated safety and a high degree of efficacy. These therapies are transforming care for select cancers and are primed to do so across a broader set of indications,” said Rebecca Luse of Deep Track Capital.

Rebecca Luse说：“放射性药物现在被认为是一种逻辑上可行的治疗方式，已经证明其安全性和高度的疗效，这些疗法正在改变对特定癌症的治疗方式，并准备在更广泛的适应症中这样做，轨道资本。

“Mariana Oncology’s pipeline is innovative and differentiated from most existing radiopharmaceutical companies. We are compelled by the broader opportunity for radiopharmaceuticals beyond prostate cancer and look forward to supporting Mariana Oncology’s success along with their seasoned leadership team and strong syndicate.”.

“Mariana Oncology的管道具有创新性，与大多数现有的放射性制药公司有所区别，我们受到前列腺癌以外放射性药物更广泛机会的推动，并期待支持Mariana Oncology的成功以及经验丰富的领导团队和强大的集团“。

“The promising nature of Mariana Oncology’s pipeline is particularly exciting when we look at the possible positive impact on patients,” said Geert-Jan Mulder, M.D., Managing Partner of Forbion. “MC-339 has the potential to transform the treatment of small cell lung cancer with the targeted delivery of an actinium payload leveraging the advantages of peptides for enhanced tumoral distribution.

管理合作伙伴Forbion的Geert-Jan Mulder博士说：“当我们考虑对患者可能产生的积极影响时，Mariana Oncology的管道的前景特别令人兴奋。“MC-339有可能利用肽的优势增强肿瘤分布，通过靶向递送act有效负载来改变小细胞肺癌的治疗方法。

We look forward to Mariana Oncology’s evolution into a clinical-stage company with the potential to efficiently deliver an effective new standard of care to patients in the future.”.

我们期待Mariana Oncology发展成为一家临床阶段公司，有可能在未来为患者提供有效的新护理标准“。

In conjunction with this financing, Rebecca Luse from Deep Track Capital and Geert-Jan Mulder, M.D., from Forbion will join the Board of Directors.

结合这一融资，来自Deep Track Capital的Rebecca Luse和来自Forbion的Geert-Jan Mulder，M.D。将加入董事会。

About Mariana Oncology

关于玛丽安娜肿瘤学

Mariana Oncology is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted peptide-based radiopharmaceuticals. The company’s radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets to deliver alpha or beta-emitting radionuclide payloads.

Mariana Oncology是一家完全集成的下一代放射性药物公司，专注于开创一类新型靶向肽基放射性药物。该公司的放射性药物由合理设计的结合物组成，针对精心挑选的生物靶标，提供α或β发射放射性核素有效载荷。

By engineering molecules designed to penetrate solid tumors better than antibodies and deliver optimized high radiation activity doses without the side effects associated with chemotherapy and toxin-based strategies, Mariana Oncology aims to transform the treatment of cancer. For more information visit www.marianaoncology.com..

通过设计用于比抗体更好地穿透实体瘤的分子并提供优化的高辐射活性剂量而没有与化学疗法和基于毒素的策略相关的副作用，Mariana肿瘤学旨在改变癌症的治疗。欲了解更多信息，请访问www.marianaoncology.com。。

About MC-339

关于MC-339

MC-339 is a peptidic small molecule engineered to carry an actinium payload for the targeted radiopharmaceutical therapy of small cell lung cancer. Small cell lung cancer is a rare, aggressive form of lung cancer characterized by rapid tumor progression, a low patient survival rate, and limited therapeutic options.

MC-339是一种肽类小分子，经过工程改造，可携带act有效负载，用于小细胞肺癌的靶向放射性药物治疗。小细胞肺癌是一种罕见的侵袭性肺癌，其特征在于肿瘤快速进展，患者存活率低和治疗选择有限。

Of the approximately 2.2 million new lung cancer cases worldwide in 2020, small cell lung cancer represents approximately 10-15% of these cases. The target for MC-339 has not been disclosed..

在2020年全球约220万新发肺癌病例中，小细胞肺癌约占这些病例的10-15%。MC-339的目标尚未公开。。